HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies

A massive block deal unfolded in the pharmaceutical sector as major institutional players shook up the equity structure of Corona Remedies Limited. High-profile investors, including HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA), stepped in to acquire significant stakes during this high-value transaction.

Details of the Massive Divestment

On June 17, 2026, a significant portion of the equity in Corona Remedies was offloaded through a coordinated block deal on the stock exchange. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.

Adding to the selling pressure, Anchor Partners also participated in the divestment, offloading 1,61,861 shares at the same price of ₹1,730 per share, worth roughly ₹28 crore. When combined, these two entities successfully exited positions worth a total of approximately ₹776.9 crore in the pharmaceutical company.

Institutional Heavyweights Drive the Buy Side

The transaction saw aggressive participation from twelve different institutional investors, signaling strong confidence in Corona Remedies' long-term prospects. HDFC Mutual Fund emerged as the dominant force on the buy side, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value.

Other prominent domestic and international players included:

• Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
• Aberdeen Asian Smaller Companies Investment Trust Plc: Acquired 4,50,868 shares for approximately ₹78 crore.
• Invesco Mutual Fund: Picked up 2,89,017 shares worth about ₹50 crore.
• Kotak Mahindra Mutual Fund: Bought 1,61,861 shares, mirroring the exact quantity sold by Anchor Partners, in a deal worth ₹28 crore.

Global and Specialized Funds Join the Fold

The deal attracted significant interest from global sovereign wealth funds and emerging market specialists. The Abu Dhabi Investment Authority (ADIA) entered the fray by purchasing 39,130 shares valued at ₹6.8 crore.

اکوسیستم WhiteOak و صندوق‌های Aberdeen نیز اشتیاق قابل‌توجهی نشان دادند. صندوق Aberdeen Standard Sicav I - Asian Smaller Companies Fund تقریباً ۴۷.۴ کرور روپیه سرمایه‌گذاری کرد، در حالی که WhiteOak Capital Mutual Fund و Ashoka WhiteOak Emerging Markets Equity Fund به ترتیب سهام‌هایی به ارزش ۲۵.۱ کرور و ۲۵.۷ کرور روپیه خریداری کردند. شرکت Factory Mutual Insurance Company و صندوق TCW White Oak Emerging Markets Equity Fund نیز ورودهای کوچک‌تری داشتند که گروه متنوعی از تأمین‌کنندگان سرمایه بسیار پیشرفته را تکمیل کرد.

نکات کلیدی

• خروج بزرگ: Sepia Investments و Anchor Partners مجموعاً سهامی به ارزش تقریباً ۷۷۶.۹ کرور روپیه در Corona Remedies را فروختند.
• تسلط HDFC MF: صندوق سرمایه‌گذاری HDFC Mutual Fund با سرمایه‌گذاری ۴۲۳.۹ کرور روپیه، بزرگترین خریدار بود و بیش از ۵۰ درصد از ارزش کل معامله را به خود اختصاص داد.
• اعتماد نهادی: مشارکت غول‌های جهانی مانند ADIA و صندوق‌های مختلف Aberdeen و WhiteOak، نشان‌دهنده علاقه شدید نهادها به این شرکت در قیمت ۱,۷۳۰ روپیه است.